Zhitong Finance App News, Hotjing Biotech (688068.SH) announced that in order to integrate the company's and affiliated companies' in vitro diagnostic business, the company plans to acquire 100% of the shares of Beijing Kaijing Gene Technology Co., Ltd. (“Shunjing Gene”) held by the affiliated company Beijing Shunjing Biomedical Technology Co., Ltd. (“Shunjing Pharmaceutical”). The transfer price for this transaction was 11 million yuan, all of which were paid in cash.
According to reports, Kaijing Gene was founded in 2016 and is a biotechnology service company specializing in R&D, production and sales of in vitro diagnostic reagent raw materials, providing high-quality antigen and antibody raw materials and technical services for in vitro diagnostic reagent manufacturers. It focuses on the establishment and application of biotechnology platforms. Currently, it has various technical platforms such as genetic recombination platforms, protein expression and purification platforms, hybrid tumor technology platforms, and genetically-engineered antibody expression platforms.
The company said that this transaction can optimize the company's business structure and help unify the in vitro diagnosis business of the company and affiliated companies, so that the company fully has the entire industry chain business from upstream key bioactive materials for in vitro diagnosis to R&D, production and sales of in vitro diagnostic reagents and instruments, which helps the company to further focus on the development of its main business and meet the company's actual business and steady development needs.